Huisheng Chen

Shenyang, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 36 publications

Endovascular Thrombectomy versus Medical Management in Patients Presenting Beyond 24 Hours of Last Known Well and With FLAIR Vascular Hyperintensities-DWI Mismatch.

Endovascular Thrombectomy versus Medical Management in Patients Presenting Beyond 24 Hours of Last Known Well and With FLAIR Vascular Hyperintensities-DWI Mismatch.

Journal: World neurosurgery

Published: March 02, 2026

Functional Outcomes of Human Urinary Kallindinogenases in Treatment of Acute Ischemic Stroke.

Functional Outcomes of Human Urinary Kallindinogenases in Treatment of Acute Ischemic Stroke.

Journal: Stroke

Published: September 29, 2025

Efficacy and Safety of Adjunctive Cenobamate in Chinese Participants with Focal Seizure.

Efficacy and Safety of Adjunctive Cenobamate in Chinese Participants with Focal Seizure.

Journal: Advances in therapy

Published: September 12, 2025

Rimegepant orally disintegrating tablet 75 mg for acute treatment of migraine in adults from China: a subgroup analysis of a double-blind, randomized, placebo-controlled, phase 3 clinical trial.

Rimegepant orally disintegrating tablet 75 mg for acute treatment of migraine in adults from China: a subgroup analysis of a double-blind, randomized, placebo-controlled, phase 3 clinical trial.

Journal: The journal of headache and pain

Published: December 12, 2023

Thrombolysis with Recombinant Human Prourokinase 4.5-6 h After Acute Ischemic Stroke: A Phase IIa, Randomized, and Open-Label Multicenter Clinical Trial.

Thrombolysis with Recombinant Human Prourokinase 4.5-6 h After Acute Ischemic Stroke: A Phase IIa, Randomized, and Open-Label Multicenter Clinical Trial.

Journal: CNS drugs

Published: November 02, 2023

Geographic differences in pharmacotherapy patterns and outcomes of acute ischemic stroke in China.

Geographic differences in pharmacotherapy patterns and outcomes of acute ischemic stroke in China.

Journal: BMC neurology

Published: July 28, 2023

Efficacy and Safety of Recombinant Human Prourokinase in the Treatment of Acute Ischemic Stroke Within 4.5 Hours of Stroke Onset: A Phase 3 Randomized Clinical Trial.

Efficacy and Safety of Recombinant Human Prourokinase in the Treatment of Acute Ischemic Stroke Within 4.5 Hours of Stroke Onset: A Phase 3 Randomized Clinical Trial.

Journal: JAMA network open

Published: July 25, 2023

Efficacy and Safety of Butylphthalide in Patients With Acute Ischemic Stroke: A Randomized Clinical Trial.

Efficacy and Safety of Butylphthalide in Patients With Acute Ischemic Stroke: A Randomized Clinical Trial.

Journal: JAMA neurology

Published: June 26, 2023

Vav1 promotes inflammation and neuronal apoptosis in cerebral ischemia/reperfusion injury by upregulating microglial and NLRP3 inflammasome activation.

Vav1 promotes inflammation and neuronal apoptosis in cerebral ischemia/reperfusion injury by upregulating microglial and NLRP3 inflammasome activation.

Journal: Neural regeneration research

Published: June 07, 2023

Effect of weekend versus weekday admission on the mortality of acute ischemic stroke patients in China: an analysis of data from the Chinese acute ischemic stroke treatment outcome registry.

Effect of weekend versus weekday admission on the mortality of acute ischemic stroke patients in China: an analysis of data from the Chinese acute ischemic stroke treatment outcome registry.

Journal: Frontiers in neurology

Published: April 16, 2023

Estimated Burden of Stroke in China in 2020.

Estimated Burden of Stroke in China in 2020.

Journal: JAMA network open

Published: March 02, 2023

Prevalence of stroke in China, 2013-2019: A population-based study.

Prevalence of stroke in China, 2013-2019: A population-based study.

Journal: The Lancet regional health. Western Pacific

Published: December 12, 2022

Showing 1-12 of 36

Last Updated: 09/26/2026